Cited by 793Cancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesImmune cells in cancer

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Open access
Zhang, Yuanyuan, Chen, Hongyan, Mo, Hongnan, Hu, Xueda, Gao, Ranran, Zhao, Yahui, Liu, Baolin, Niu, Lijuan +12 more·2021·Cancer Cell

Abstract

In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine the immune cell dynamics in 22 patients with advanced TNBC treated with paclitaxel or its combination with the anti-PD-L1 atezolizumab. We demonstrate that high levels of baseline CXCL13 + T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy. In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13 + T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy. Our data highlight the importance of CXCL13 + T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.09.010

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These CD8+ T cell subsets show different responses to anti-PD(L)-1 therapies, with TCF7+ Tpex cells demonstrated critical for ICB response in mouse tumor models and cancers.

    “These cell subsets show different responses to anti-PD(L)-1 therapies,”

    From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [19]

    The Results report different changes in T-cell subsets after paclitaxel versus paclitaxel plus atezolizumab, supporting the claim that subsets respond differently to treatment. They also link CD8-CXCL13 cells to PD-L1 blockade response, but the cited passages do not demonstrate that TCF7+ Tpex cells are critical for ICB response in mouse tumor models and cancers. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Applying ICB and combination therapies as neoadjuvant treatments provides an opportunity to observe immune cell dynamics in the tumor microenvironment with temporal samples.

    “Applying ICB and combination therapies as neoadjuvant treatments provides an opportunity to observe immune cell dynamics in tumor microenvironment (TME) with temporal samples.”

    From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [19]

    The Methods describe tumor biopsies collected before treatment and four weeks after treatment began, supporting the use of temporal samples to observe immune-cell dynamics. But the paper says only some locally advanced patients received neoadjuvant therapy; all tumor samples in the PD-L1-blockade combination group came from metastatic sites after breast surgery. It therefore does not establish the claimed opportunity specifically for neoadjuvant ICB combination treatment. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., Wang, Y., Chang, Q., Gong, T., Guan, X., Hu, T., Qian, T., Xu, B., Ma, F., Zhang, Z., & Liu, Z.
Affiliations
  • Peking University (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Corresponding author
  • Xu, Binghe
  • Ma, Fei
  • Zhang, Zemin
  • Liu, Zhihua
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-12
Volume
39
Issue
12
Pages
1578-1593.e8
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3205385275
Cited by
783
References
77
Citations by year
2026: 135 · 2025: 206 · 2024: 183 · 2023: 158 · 2022: 93 · 2021: 8
FWCI
41.16
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (31991171, 81988101, 82030089, 91942307)
  • Chinese Academy of Meteorological Sciences (2016-I2M-1-001, 2017-I2M-3-004, 2019-I2M-1-003)
  • Peking University
  • Beijing Municipal Science and Technology Commission (Z201100005320014)
  • National Key Research and Development Program of China (2018YFC1312101, 2020YFA0803300)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
triple-negative breast cancer, PD-L1 blockade, atezolizumab, paclitaxel, immune cell dynamics, lymphoid tissue inducer cells, follicular B cells, conventional type 1 dendritic cells, single-cell RNA sequencing, single-cell ATAC-seq
MeSH terms
Immune Checkpoint Inhibitors, Female, Humans, Single-Cell Analysis, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review